CN1468098A - 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物 - Google Patents

基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物 Download PDF

Info

Publication number
CN1468098A
CN1468098A CNA018168604A CN01816860A CN1468098A CN 1468098 A CN1468098 A CN 1468098A CN A018168604 A CNA018168604 A CN A018168604A CN 01816860 A CN01816860 A CN 01816860A CN 1468098 A CN1468098 A CN 1468098A
Authority
CN
China
Prior art keywords
pravastatin
sodium
pravastatin sodium
solution
pure basically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018168604A
Other languages
English (en)
Chinese (zh)
Inventor
v
V·克里
L·德克
I·福尔加克斯
C·绍博
ɼ�����
A·E·纳吉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Works PLC
Original Assignee
Biogal Gyogyszergyar Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1468098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Gyogyszergyar Rt filed Critical Biogal Gyogyszergyar Rt
Publication of CN1468098A publication Critical patent/CN1468098A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA018168604A 2000-10-05 2001-10-05 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物 Pending CN1468098A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
US60/238,278 2000-10-05

Publications (1)

Publication Number Publication Date
CN1468098A true CN1468098A (zh) 2004-01-14

Family

ID=22897222

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018168604A Pending CN1468098A (zh) 2000-10-05 2001-10-05 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物

Country Status (18)

Country Link
EP (1) EP1330245A4 (enExample)
JP (6) JP3737801B2 (enExample)
KR (1) KR20030059173A (enExample)
CN (1) CN1468098A (enExample)
AU (1) AU2002211462A1 (enExample)
CA (1) CA2422744A1 (enExample)
CZ (1) CZ20031166A3 (enExample)
HR (1) HRP20030347A2 (enExample)
HU (1) HUP0400913A2 (enExample)
IL (1) IL155194A0 (enExample)
IS (1) IS6766A (enExample)
MX (1) MXPA03002963A (enExample)
NO (1) NO20031532L (enExample)
NZ (1) NZ525631A (enExample)
PL (1) PL361230A1 (enExample)
SK (1) SK5232003A3 (enExample)
WO (1) WO2002030415A1 (enExample)
ZA (1) ZA200302313B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114031496A (zh) * 2021-11-30 2022-02-11 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
EP1481674B1 (en) * 1999-11-30 2008-01-02 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
ES2273737T3 (es) * 1999-11-30 2007-05-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedimiento para la recuperacion de compuestos de estatina de un caldo de fermentacion.
IL150187A0 (en) 1999-12-14 2002-12-01 Biogal Pharmaceutical Co Ltd Novel forms of pravastatin sodium
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP2033636A1 (en) 2003-11-24 2009-03-11 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method of purifying pravastatin
MX2007001553A (es) 2004-08-06 2008-03-07 Transform Pharmaceuticals Inc Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
ES2254028B1 (es) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de pravastatina sodica purificada.
MX2007010431A (es) * 2005-02-25 2007-10-11 Teva Pharma Proceso para purificar tadalafil.
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (enExample) * 1973-09-29 1977-06-11
CH624956A5 (de) * 1975-02-07 1981-08-31 Glaxo Operations Ltd Verfahren zur entfernung von verunreinigungen aus clavulansaeure.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
JPS5890509A (ja) * 1981-11-25 1983-05-30 Sankyo Co Ltd 高コレステロ−ル血症治療用組成物
JPH01190661A (ja) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk ４，４′−ジヒドロキシジフエニルスルホンの精製法
JP2739328B2 (ja) * 1988-09-14 1998-04-15 日本ケミファ株式会社 ベンズイミダゾール化合物の精製方法
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (ja) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd 光学活性α−カルバモイルアルカン酸誘導体およびその製法
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
DK0754239T3 (da) * 1994-03-31 1998-05-18 Cultor Oy Fremgangsmåde til indvinding af natamycin
HU221636B1 (hu) * 1995-08-03 2002-12-28 Plus Chemicals B.V. Szelektív eljárás acilezett vegyületek dezacilezésére
JPH09124655A (ja) * 1995-11-01 1997-05-13 Sankyo Co Ltd 新規スクアレンシンターゼ阻害活性化合物
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
JP2000229855A (ja) * 1998-12-07 2000-08-22 Satoshi Takebe プラバスタチンナトリウム錠
HRP20010577B1 (en) * 1999-02-03 2005-12-31 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
ES2273737T3 (es) * 1999-11-30 2007-05-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedimiento para la recuperacion de compuestos de estatina de un caldo de fermentacion.
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114031496A (zh) * 2021-11-30 2022-02-11 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Also Published As

Publication number Publication date
JP2015212300A (ja) 2015-11-26
NO20031532D0 (no) 2003-04-04
ZA200302313B (en) 2004-03-25
JP2013128486A (ja) 2013-07-04
IS6766A (is) 2003-04-01
IL155194A0 (en) 2003-11-23
SK5232003A3 (en) 2004-06-08
EP1330245A4 (en) 2004-10-20
KR20030059173A (ko) 2003-07-07
WO2002030415A9 (en) 2002-10-31
NO20031532L (no) 2003-04-04
PL361230A1 (en) 2004-10-04
AU2002211462A1 (en) 2002-04-22
CA2422744A1 (en) 2002-04-18
JP3737801B2 (ja) 2006-01-25
MXPA03002963A (es) 2005-01-25
JP2009268479A (ja) 2009-11-19
WO2002030415A1 (en) 2002-04-18
NZ525631A (en) 2005-05-27
JP2005013238A (ja) 2005-01-20
JP2004510817A (ja) 2004-04-08
HUP0400913A2 (en) 2006-11-28
HRP20030347A2 (en) 2005-04-30
EP1330245A1 (en) 2003-07-30
CZ20031166A3 (cs) 2004-04-14
JP2006036781A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
CN1468098A (zh) 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
CN1433305A (zh) 从发酵肉汤中回收抑素化合物的方法
US6936731B2 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US20080300305A1 (en) Method of purifying pravastatin
US20050215636A1 (en) Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
EP1327624A1 (en) Method of purifying pravastatin or its pharmacologically acceptable salt
CN1886125A (zh) 普伐他汀的纯化方法
EP1481674B1 (en) Process for recovering statin compounds from a fermentation broth
CA2581031A1 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
HK1071522A (en) Process for recovering statin compounds from a fermentation broth
EP1798214A1 (en) Process for recovering statin compounds from a fermentation broth
HK1053642A (en) Method of purifying pravastatin or its pharmacologically acceptable salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication